266 related articles for article (PubMed ID: 34653598)
1. Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas.
Zing N; Fischer T; Federico M; Chiattone C; Ferreri AJM
Crit Rev Oncol Hematol; 2021 Nov; 167():103496. PubMed ID: 34653598
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
3. Central Nervous System Relapse in T and NK cell Lymphomas.
Taranto EP; Barta SK; Bhansali RS
Curr Hematol Malig Rep; 2023 Dec; 18(6):243-251. PubMed ID: 37620711
[TBL] [Abstract][Full Text] [Related]
4. Primary and secondary central nervous system mature T- and NK-cell lymphomas.
Pang Y; Chihara D
Semin Hematol; 2021 Apr; 58(2):123-129. PubMed ID: 33906722
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.
Ferreri AJ; Assanelli A; Crocchiolo R; Ciceri F
Hematol Oncol; 2009 Jun; 27(2):61-70. PubMed ID: 19247977
[TBL] [Abstract][Full Text] [Related]
6. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment.
van Besien K; Gisselbrecht C; Pfreundschuh M; Zucca E
Leuk Lymphoma; 2008; 49 Suppl 1():52-8. PubMed ID: 18821433
[TBL] [Abstract][Full Text] [Related]
7. [Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas].
Kumiega B; Jurczak W; Fornagiel S; Dzietczenia J; Skotnicki AB
Przegl Lek; 2013; 70(4):187-90. PubMed ID: 23991555
[TBL] [Abstract][Full Text] [Related]
8. Central Nervous System Involvement of Natural Killer and T Cell Neoplasms.
Aaroe AE; Nevel KS
Curr Oncol Rep; 2019 Mar; 21(5):40. PubMed ID: 30919085
[TBL] [Abstract][Full Text] [Related]
9. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study.
Ellin F; Landström J; Jerkeman M; Relander T
Blood; 2015 Jul; 126(1):36-41. PubMed ID: 25957393
[TBL] [Abstract][Full Text] [Related]
12. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
13. Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system.
Li X; Yu H; Fu X; Zhang L; Li X; Li L; Wang X; Sun Z; Zhang X; Li Z; Wu J; Chang Y; Yan J; Zhou Z; Nan F; Wu X; Tian L; Zhang M
Hematol Oncol; 2023 Apr; 41(2):267-274. PubMed ID: 34061378
[TBL] [Abstract][Full Text] [Related]
14. Risk of CNS dissemination in extranodal lymphomas.
Ferreri AJ
Lancet Oncol; 2014 Apr; 15(4):e159-69. PubMed ID: 24694639
[TBL] [Abstract][Full Text] [Related]
15. Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry.
Mocikova H; Pytlík R; Benesova K; Janikova A; Duras J; Sykorova A; Steinerova K; Prochazka V; Campr V; Belada D; Trneny M
Front Oncol; 2022; 12():874462. PubMed ID: 35646641
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.
Hollender A; Kvaloy S; Nome O; Skovlund E; Lote K; Holte H
Ann Oncol; 2002 Jul; 13(7):1099-107. PubMed ID: 12176790
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.
Yi JH; Kim JH; Baek KK; Lim T; Lee DJ; Ahn YC; Kim K; Kim SJ; Ko YH; Kim WS
Ann Oncol; 2011 Jul; 22(7):1636-1643. PubMed ID: 21220520
[TBL] [Abstract][Full Text] [Related]
19. The risk of CNS involvement in aggressive lymphomas in the rituximab era.
Benevolo G; Chiappella A; Vitolo U
Expert Rev Hematol; 2013 Dec; 6(6):643-52. PubMed ID: 24168678
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.
Haioun C; Besson C; Lepage E; Thieblemont C; Simon D; Rose C; Tilly H; Sonet A; Lederlin P; Attal M; Brière J; Reyes F
Ann Oncol; 2000 Jun; 11(6):685-90. PubMed ID: 10942056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
